GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » DexCom Inc (NAS:DXCM) » Definitions » EV-to-EBITDA

DexCom (DexCom) EV-to-EBITDA : 49.39 (As of Apr. 29, 2024)


View and export this data going back to 2005. Start your Free Trial

What is DexCom EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, DexCom's enterprise value is $49,169 Mil. DexCom's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $996 Mil. Therefore, DexCom's EV-to-EBITDA for today is 49.39.

The historical rank and industry rank for DexCom's EV-to-EBITDA or its related term are showing as below:

DXCM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -778.81   Med: -58.72   Max: 2659.49
Current: 49.39

During the past 13 years, the highest EV-to-EBITDA of DexCom was 2659.49. The lowest was -778.81. And the median was -58.72.

DXCM's EV-to-EBITDA is ranked worse than
90.74% of 486 companies
in the Medical Devices & Instruments industry
Industry Median: 15.405 vs DXCM: 49.39

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-29), DexCom's stock price is $124.91. DexCom's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $1.550. Therefore, DexCom's PE Ratio for today is 80.59.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


DexCom EV-to-EBITDA Historical Data

The historical data trend for DexCom's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexCom EV-to-EBITDA Chart

DexCom Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 92.23 91.99 136.42 76.83 52.03

DexCom Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74.53 72.17 45.13 52.03 54.87

Competitive Comparison of DexCom's EV-to-EBITDA

For the Medical Devices subindustry, DexCom's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexCom's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, DexCom's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where DexCom's EV-to-EBITDA falls into.



DexCom EV-to-EBITDA Calculation

DexCom's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=49168.946/995.6
=49.39

DexCom's current Enterprise Value is $49,169 Mil.
DexCom's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $996 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DexCom  (NAS:DXCM) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

DexCom's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=124.91/1.550
=80.59

DexCom's share price for today is $124.91.
DexCom's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.550.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


DexCom EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of DexCom's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


DexCom (DexCom) Business Description

Address
6340 Sequence Drive, San Diego, CA, USA, 92121
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Executives
Sadie Stern officer: Chief Human Resources Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Steven R Altman director
Kevin R Sayer director
Jereme M Sylvain officer: SVP, Finance & CAO 6340 SEQUENCE DRIVE, SAN DIEGO X1 92121
Jacob Steven Leach officer: SVP, Research & Development 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Nicholas Augustinos director 754 GRAND VIEW AVENUE, SAN FRANCISCO CA 94114
Micheal Jon Brown officer: EVP, Chief Legal Officer 6340 SEQUENCE DR, SAN DIEGO CA 92121
Steven Robert Pacelli officer: Vice President Legal Affairs 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Girish Naganathan officer: EVP Chief Technology Officer C/O DEXCOM, INC., 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Barry J. Regan officer: EVP Operations 1023 CHERRY ROAD, MEMPHIS TN 38117
Bridgette P Heller director TECH DATA CORPORATION, 5350 TECH DATA DRIVE, CLEARWATER FL 33760
Matthew Vincent Dolan officer: * 6340 SEQUENCE DR, SAN DIEGO CA 92121
Rimma Driscoll director C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Shelly Ramasamy Selvaraj officer: SVP Information Technology 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Paul R Flynn officer: EVP, Global Revenue 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121

DexCom (DexCom) Headlines

From GuruFocus

Q3 2021 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2021 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Dexcom Inc Investor Day Transcript

By GuruFocus Research 01-22-2024

Dexcom Inc at Wells Fargo Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Q1 2023 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2022 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024